References
- Siddiqui AA, Kushnoor A, and Wani SM. Synthesis and hypotensive activity of some 6-(substituted aryl)-4-methyl-2,3-dihydropyridazin-3-ones. Indian J Chem-B 2004;43B:1574–1579
- Banerjee PS, Sharma PK, and Nema RK. Synthesis and anticonvulsant activity of pyridazinone derivatives. Int J Chem Tech Research 2009;1:522–525
- Tanaka H, Kirihara S, Yasumatsu H, Yakushiji T, and Nakao T. Synthesis and evaluation of novel 2-aryl-2,5,6,7-tetrahydro-3H-thieno[2′,3′:6,7]cyclohepta[1,2-c]pyridazin-3-ones and 2-aryl-5,6-dihydrothieno[2,3-h]cinnolin-3(2H)-ones as anxiolytics. Eur J Med Chem 1997;32:607–615.
- Pinna GA, Curzu MM, Murineddu G, Chelucci G, Cignarella G, Menta E et al. Preparation of thieno[3,2-h]cinnolinones as matrix metalloproteinase inhibitors. Arch Pharm (Weinheim) 2000;333:37–47.
- Pau A, Asproni B, Boatto G, Grella GE, De Caprariis P, Costantino L et al. Synthesis and aldose reductase inhibitory activities of novel thienocinnolinone derivatives. Eur J Pharm Sci 2004;21:545–552.
- Kwon SK, Moon A. Synthesis of 3-alkylthio-6-allylthiopyridazine derivatives and their antihepatocarcinoma activity. Arch Pharm Res 2005;28:391–394.
- Sönmez M, Berber I, Akbas E. Synthesis, antibacterial and antifungal activity of some new pyridazinone metal complexes. Eur J Med Chem 2006;41:101–105.
- Harris RR, Black L, Surapaneni S, Kolasa T, Majest S, Namovic MT et al. ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor. J Pharmacol Exp Ther 2004;311:904–912.
- Estevez I, Ravina E, Sotelo E. Synthesis of 6-aryl-5-amino-3(2H)-pyridazinones as potential platelet aggregation inhibitors. J Heterocyclic Chem 1998;35:1421–1428.
- Haider N, Hartmann RW, Steinwender A. Synthesis of 2- [2-(1-imidazolyl)ethyl]-4-phenylcycloalka [ g ] phthalazin-1(2H)-ones as thromboxane A 2 synthase inhibitors, Arch Pharm Pharm Med Chem 1999;332:408–409.
- Amgad G, Habeeb PN, Parveen R, Edward EK. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: Replacement of sulphonamide and methylsulfonyl pharmacophores by an azido bioisosters. J Med Chem 2001;44:3039–3042.
- Sotelo E, Fraiz N, Yáñez M, Laguna R, Cano E, Brea J et al. Pyridazines. Part 28: 5-alkylidene-6-phenyl-3(2H)-pyridazinones, a new family of platelet aggregation inhibitors. Bioorg Med Chem Lett 2002;12:1575–1577.
- Coelho A, Sotelo E, Fraiz N, Yáñez M, Laguna R, Cano E et al. Pyridazines. Part 36: Synthesis and antiplatelet activity of 5-substituted-6-phenyl-3(2H)-pyridazinones. Bioorg Med Chem Lett 2004;14:321–324.
- Van der Mey M, Boss H, Couwenberg D, Hatzelmann A, Sterk GJ, Goubitz K et al. Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones. J Med Chem 2002;45:2526–2533.
- Van der Mey M, Bommelé KM, Boss H, Hatzelmann A, Van Slingerland M, Sterk GJ et al. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents. J Med Chem 2003;46:2008–2016.
- Gilchrest BA, Eller MS. Cancer therapeutics: smart and smarter. Drugs of the Future 2009;34:205–216.
- Pau A, Murineddu G, Asproni B, Murruzzu C, Grella GE, Pinna GA et al. Synthesis and cytotoxicity of novel hexahydrothienocycloheptapyridazinone derivatives. Molecules 2009;14:3494–3508.
- Drew J. Drug discovery: A historical perspective. Science 2000;287:1960–1964.
- Supuran CT and Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Exp Opin Ther Patents 2000;10:575–600.
- Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors. Curr Med Chem Immunol Endoc Metab Agents 2001;1:61–97.
- Maren TH. Relations between structure and biological activity of sulfonamides. Annu Rev Pharmacol Toxicol 1976;16:309–327.
- Boyd AE 3rd. Sulfonylurea receptors, ion channels, and fruit flies. Diabetes 1988;37:847–850.
- Thornber CW. Isosterism and molecular modification in drug design. Chem Soc Rev 1979;8:563–580.
- Ogden RC, Flexner CW. (2001). Protease Inhibitors in AIDS Therapy. New York, Basel: Marcel Dekker.
- Supuran C, Scozzafava A, Mastrolorenzo A. Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics. Expert Opin Ther Patents 2001;11:221–259.
- Scozzafava A, Supuran CT. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J Med Chem 2000;43:3677–3687.
- Casini A, Scozzafava A, Mastrolorenzo A, Supuran LT. Sulfonamides and sulfonylated derivatives as anticancer agents. Curr Cancer Drug Targets 2002;2:55–75.
- Khanna IK, Weier RM, Yu Y, Collins PW, Miyashiro JM, Koboldt CM et al. 1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2. J Med Chem 1997;40:1619–1633.
- Bashir R. (2010). Thesis, Synthesis of novel heterocyclic compounds of pharmaceutical interest. New Delhi, India: Jamia Hamdard.
- Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med 1962;111:544–547.
- Rathish IG, Javed K, Ahmad S, Bano S, Alam MS, Pillai KK et al. Synthesis and antiinflammatory activity of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide. Bioorg Med Chem Lett 2009;19:255–258.